Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

/in

The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region Significantly enhances Hansa’s financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization Lund, […]

Read more

Hansa Biopharma participating at LSX Nordic Congress

/in

Lund, Sweden, 18 May. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled “Scaling Success: Key Drivers for Growing Nordic Biotechs” at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026. Read more…

Read more

Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

/in

Lund, Sweden, 12 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq in New York, from 17:00-17:30 EDT, on Tuesday 19 May, 2026. Read more…

Read more

Poolbeg Pharma plc – POLB 001 poster to be presented at EHA 2026 Congress

/in

13 May 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it will present data on POLB 001 at the European Hematology Association Congress (“EHA”), taking place 11-14 June 2026 in Stockholm, Sweden. Read more…

Read more

Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026

/in

TX001 is an engineered Regenerative Macrophage Therapy for end-stage liver disease (ESLD) with anti-inflammatory and anti-fibrotic properties These new preclinical data demonstrate RTX001’s pharmacology, safety, tolerability, and efficacy in mouse models, with reduced fibrosis and inflammation observed Results confirm RTX001’s positive preclinical safety and therapeutic profile ahead of interim results from Resolution’s Phase I/II EMERALD […]

Read more